Abeona Therapeutics (ABEO) vs Clinuvel Pharmaceuticals (CUVL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed Clinuvel Pharmaceuticals (CUVL) over the past year, losing 3.2% versus a loss of 29.7%. Over five years, ABEO leads with a -77.7% price change compared with -80.9% for CUVL. Abeona Therapeutics is the larger company by market cap ($285.1 million vs $282.0 million), about 1.0 times the size.
Clinuvel Pharmaceuticals pays a dividend yielding 0.90%, while Abeona Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | CUVL |
|---|---|---|
| Share price | $4.99 | $5.59 |
| Market cap | $285.06M | $281.97M |
| 1-day change | -1.87% | -3.71% |
| YTD return | -3.61% | -31.60% |
| 1-year return | -3.24% | -29.70% |
| 5-year return | -77.67% | -80.95% |
| P/E ratio (TTM) | — | 12.41 |
| EPS (TTM) | $-1.18 | $0.45 |
| Dividend yield | 0.00% | 0.90% |
| Annual dividend | $0.00 | $0.05 |
| 52-week high | $7.65 | $8.92 |
| 52-week low | $4.00 | $5.57 |
| Distance from 52-week high | -34.84% | -37.39% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +278.74% | — |
| Average volume | 1.41M | 12.84K |
| Shares outstanding | 57.18M | 50.49M |
| Employees | 226 | — |
| Sector | Health Care | Miscellaneous |
| Industry | Biotechnology: Pharmaceutical Preparations | Miscellaneous |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABEO has outperformed CUVL by 26.5 percentage points over the past year.
- The two companies sit in different sectors: Abeona Therapeutics in Health Care and Clinuvel Pharmaceuticals in Miscellaneous.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Clinuvel Pharmaceuticals
CUVL stock →Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Miscellaneous · Miscellaneous
ABEO vs CUVL FAQ
Which is bigger, Abeona Therapeutics or Clinuvel Pharmaceuticals?
Abeona Therapeutics (ABEO) is larger, with a market capitalization of $285.06M compared with $281.97M for Clinuvel Pharmaceuticals (CUVL).
Which stock has performed better over the past year, ABEO or CUVL?
ABEO returned -3.24% over the past 12 months, compared with -29.70% for CUVL (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Abeona Therapeutics or Clinuvel Pharmaceuticals?
Clinuvel Pharmaceuticals pays a dividend yielding 0.90%, while Abeona Therapeutics does not currently pay a regular dividend.
Are Abeona Therapeutics and Clinuvel Pharmaceuticals in the same industry?
No. Abeona Therapeutics is in the Health Care sector, while Clinuvel Pharmaceuticals is in Miscellaneous.